
Opinion|Videos|October 28, 2024
Treatment Considerations for PSMA-Positive mCRPC Patients
Author(s)Neal Shore, MD, FACS
Key Takeaways
Neal Shore, MD, FACS, highlights the exciting advancements in radioligand therapy for prostate cancer, noting that ongoing trials are exploring its use in various disease stages and settings, and emphasizes the importance of reviewing the VISION and FORE trial publications for further insights.
Advertisement
Video Player is loading.
Episodes in this series

Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Trial launches of neuromodulation therapy for erectile dysfunction after radical prostatectomy
2
PROSTOX ultra launches on US market following new data presented at ASTRO 2025
3
Published data show benefit of niraparib with AAP in HRR-deficient mCSPC
4
Rectal diazepam eases instillation of nadofaragene firadenovec in NMIBC
5